|
|
|
| home > pmps > autumn 2003 > quality: a strategic element in the success of a company |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
The convention opened with a short introduction by Sergio Dompé, President of the convention organiser and the Chairman, Prof Andrea Gazzaniga, Professor of Pharmacy at the University of Milano, who warmly welcomed the upcoming lectures by key experts from across the world in pharmaceutical quality issues. Dr Henning G Kristensen, who at present serves as the Chair of the European Commission and is a member of the Steering committee for the Certificates of Suitability of Drug Substances, spoke first, on The European Pharmacopoeia and its role in the regulatory process, highlighting the difficulties found in the integration of the Pharmacopoeias in the differing European countries.
The message was that European countries need to speak a common technical language and establish an international harmonisation of subjects. Certain uniformity in the terminology related to pharmaceutical products' qualitative characteristics and in the impurities controls, both for the active pharmaceutical ingredients (API) and excipients and for the container materials, should be reached in the next few years. In the 4th Edition of European Pharmacopoeia it is stated that those standards have to be appropriate to the needs of all people engaged in quality controls laboratories and in the manufacturers of starting materials too.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Airnov enlarges portfolio with a new and innovative addition to meet evolving customers’ needs
HAT®-B, launched in July 2022, is the latest product in the HAT product
line designed to protect test strips, pharmaceuticals, and
nutraceuticals from moisture. Capacity increased in China to produce
higher quantities of HAT-SNAP to answer soaring market demand in this
region. Sustainability continues to be a key consideration for Airnov
when designing new products.
More info >> |
|
 |
White Papers |
 |
|
Soothing the Logistical Headache of Clinical Trials
Equilibrium Travel Management
As many as 30 per cent of subjects on phase three clinical studies drop out. Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial. It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >> |
|
|
